Cell and gene therapy companies develop advanced treatments that modify, replace or engineer cells and genetic material to treat disease. The field is one of the fastest-growing areas of biotechnology and precision medicine.
This category includes companies working on:
Browse 163 UK cell and gene therapy companies below.
DNA-based gene therapy platform for intercellular therapeutic gene delivery
Bitrobius Genetics is a UK biotech developing a novel DNA-based gene therapy platform technology designed to deliver functional copies of mutated genes to cells within a target tissue or organ. Its platform is based on the principle of DNA replication and intercellular transmission, aiming to achieve broad tissue…
Cell and gene therapy supply chain orchestration software
TrakCel is a Welsh software company providing digital orchestration platforms for the management, tracking, and control of cell and gene therapy products across clinical and commercial supply chains. Its flagship platform manages chain of identity and chain of custody for personalised therapies from sample collection…
Automated bioreactor platform for GMP cell therapy manufacturing
Aglaris is a developer of automated cell manufacturing systems for advanced therapy medicinal products. Its flagship platform integrates real-time process monitoring, single-use culture cartridges, and GMP-compliant controls to enable reproducible production of CAR-T cells, mesenchymal stem cells, and other cell types…
Global bioprocess technology and life science tools provider
Cytiva is a global life sciences company providing technologies, instruments and services for biopharmaceutical research, development and manufacturing. Its UK operations span multiple sites including Amersham (protein analysis, Western blotting), Cardiff (single-use bioprocessing manufacturing, genomics R&D, magnetic…
CAR T cell therapies for blood cancer and autoimmune disease
Autolus Therapeutics is a London-based commercial-stage biopharma developing next-generation programmed T cell therapies. Its lead product AUCATZYL (obecabtagene autoleucel) received FDA approval in November 2024 and MHRA conditional marketing authorisation in 2025 for relapsed or refractory B-cell acute lymphoblastic…
University research institute advancing stem cell biology and therapeutics
Cambridge Stem Cell Institute is a University of Cambridge research institute investigating stem cell biology, tissue maintenance and disease. Its research groups study stem cell states, disease mechanisms and therapeutic applications using cell culture, genomics, imaging and experimental models. Based at Cambridge…
Precision-programmed human iPSC-derived cells for biomedical research
bit.bio is a Cambridge-based synthetic biology company that programmes human induced pluripotent stem cells into defined, mature cell types for use in pharmaceutical and academic research. Its precision cell programming technology produces consistent, characterised human cells at industrial scale, supporting drug…
Rejuvenation biology company decoding the genomics of cellular ageing reversal
clock.health is a biotechnology company developing therapies to reverse cellular ageing and extend healthspan by decoding the biological programmes that govern cell rejuvenation. Using a proprietary model in which human induced pluripotent stem cells are artificially aged then permitted to self-rejuvenate, the company…
Microfluidic avidity platform for preclinical cell therapy validation
Avigen is a contract research organisation providing preclinical validation services for cellular immunotherapies using a proprietary microfluidic platform. The platform measures cellular avidity, the total binding strength between immune and cancer cells, at high throughput using fluid shear stress, enabling…
AAV gene therapy platform and clinical pipeline for genetic disease
AskBio UK Ltd is the European headquarters of AskBio Inc., a fully integrated AAV gene therapy company and Bayer AG subsidiary. Operating from Roslin Innovation Centre, the Edinburgh site develops the company's synthetic promoter technology, data-driven gene expression control sequences that complement AskBio's Pro10…
CDMO and CRO for complex biologics and bioconjugate development
Abzena is an integrated CDMO and CRO specialising in complex biologics and bioconjugates, with cGMP facilities across the United States and a research presence in Cambridge, UK. Its services span antibody discovery, cell line development, bioconjugation and GMP manufacturing across monoclonal antibodies, antibody-drug…
Cell and gene therapy CDMO with clinical and commercial manufacturing
RoslinCT is a CDMO specialising in advanced cell and gene therapies. Operating purpose-built cGMP facilities at Edinburgh BioQuarter and in Hopkinton, Massachusetts, it provides process development, analytical testing, clinical and commercial manufacturing for autologous and allogeneic cell therapies, with particular…
Gene therapy and biologics CDMO with cGMP manufacturing in Liverpool
Pharmaron Biologics (UK) Ltd is a contract development and manufacturing organisation specialising in biologics and cell and gene therapy, operating from cGMP biomanufacturing facilities in Speke, Liverpool. The site offers end-to-end services spanning plasmid design, cell line development, viral vector process…
Microfluidic nanoparticle formulation instruments for gene and cell therapy
Unchained Labs (Royston) is a developer of microfluidic mixing instruments for nanoparticle and lipid nanoparticle formulation, spanning early-stage screening through GMP-ready production. The site's technology, developed from decades of microfluidics expertise, supports researchers formulating and scaling lipid…
High-capacity viral vector manufacturing platform for gene therapy
Icosphere Biosciences is a biotechnology company developing manufacturing technology for high-capacity gene therapy vectors. Its platform enables scalable, high-yield, contamination-free production of high capacity adenoviral vectors capable of carrying substantially more genetic material than conventional viral…
Dual-pathway AAV gene therapies for retinal degeneration
Ikarovec is a biotechnology company developing dual-pathway adeno-associated virus gene therapies for retinal diseases. Its lead candidate combines complementary mechanisms targeting complement activity, inflammation and retinal cell protection in geographic atrophy. Additional programmes target wet and intermediate…
Gene therapy platform delivering precision cancer treatments
Trogenix is a clinical-stage biotechnology company developing precision gene therapies for aggressive solid tumours. Its platform uses proprietary synthetic super-enhancers, engineered genetic constructs delivered via AAV vectors, to selectively activate in cancer cells and simultaneously trigger tumour cell death and…
Next-generation CAR T-cell therapies for solid tumours
ImmunoKey is a seed-stage biotechnology company developing CAR T-cell therapies designed to overcome the barriers limiting efficacy in solid tumours. Its proprietary platform enables multi-antigen targeting while minimising off-tumour toxicity, supported by complementary technologies to enhance T-cell persistence and…
Gene therapies targeting the ageing process and age-related disease
Genflow Biosciences is a longevity-focused biotechnology company developing gene therapies designed to slow or halt the biological ageing process and delay age-related disease. Its lead compound uses an adeno-associated viral vector to deliver a centenarian variant of the SIRT6 gene, with a pipeline spanning human and…
Sterile GMP fill/finish CMO for biologics and small molecules
Symbiosis Pharmaceutical Services is a contract manufacturing organisation specialising in sterile GMP fill/finish manufacturing of injectable drug products for clinical trials and low-volume commercial supply. Operating from a purpose-built MHRA-licensed and FDA-inspected facility in Stirling, the company handles a…